As the universe of exchange-traded funds (ETF) expands, investors are being thrust into a land of confusion. There are more than 100 different international ETFs to choose from right now. There are even three separate and unique ETFs that specialize in water. Where do investors turn?

The majority of ETF investors do not realize there are five biotech choices available for purchase. What is more amazing is that the public sees "biotech ETF" and assumes all five must be interchangeable; However, in the first 7 months of the year the biotech sector has been flat, but the five ETFs that track the sector have been all over the board. Read on as we delve a little deeper into biotech ETFs and the disparity in their returns.

Biotech Buyers Beware
I hate to be the bearer of bad news, but there is a drastic difference in ETFs that claim to track the same sector. The variations are very noticeable in the returns of the biotech ETFs in the first seven and a half months of the year. Of the five biotech ETFs the best performer year-to-date through August 16 was the SPDR S&P Biotech ETF (NYSE:XBI) with a gain of about 14%. On the opposite end of the spectrum, HOLDRS Biotech ETF (NYSE:BBH) had a loss of 12% in the same timeframe.

In monetary terms, a $100,000 investment in XBI at the beginning of the year would now be worth about $114,000 and the BBH investment a mere $88,000. The BBH must put together a 30% increase just to get to even with the XBI. Keep in mind this took place in less than eight months time.

Looking Inside the Sector
To put the numbers into perspective, the AMEX Biotech Index lost 0.3% and the S&P 500 was down 0.5% in the same period. Therefore the XBI greatly outperformed the benchmarks, and BBH was a clear laggard. The other three biotech ETFs had a much more muted start to the year: iShares NASDAQ Biotech ETF (NYSE:IBB) -1.8%, First Trust AMEX Biotech ETF (NYSE:FBT) -0.8%, and PowerShares Dynamic Biotech ETF (AMEX:PBE) 3.1%.

Stocks vs. ETFs
By delving further into the numbers and looking at all biotech stocks we follow (204 total), the case for a biotech ETF strengthens. Of the 204 biotech stocks, only 23% were able to outperform XBI. As a matter of fact, only 52% had better returns than the 12% loss of BBH.

So, why would anyone invest in a biotech stock if the odds are the ETF will be able to outperform over half the time? It is a combination of greed and perceived stock picking abilities. The greed factor comes in because investors are over confident and want to go for the big winners. There was a 2% chance investors could have picked a stock that doubled. Even though the odds are small, there is still the chance. (To learn more, see Master Your Trading Mindtraps.)

At the same time, two out of every three biotech stocks were in negative territory. Well, maybe investors do not need to get the stock that doubles, but they feel they can outperform even the best biotech ETF. There was an 18% chance the investor could have picked a stock that gained over 20%. However, the possibility of picking a stock that lost at least 20% came in at 41%. Again the numbers are not favoring stock picking.

How about the possibility of picking a biotech stock that gets hit with negative news and takes a massive hit? Unbelievably, 13% of all biotech stocks lost at least 50% in the first seven and a half months of 2007.

Inside the ETFs
The reason for the major differences in returns of the ETFs has to do with their composition. The top performer, XBI, is very diverse and its largest holding makes up less than 4% of the entire allocation. The underperformance on BBH can be directly linked to its top three holdings, which make up 75% of the entire portfolio. Genentech (NYSE:DNA) and Amgen (Nasdaq:AMGN) are the top two holdings and are considered mega-cap biotech names that have returns of -9.8% and -27.7%, respectively.

I would not consider BBH an investment option unless I had intentions of purchasing all three of its top holdings separately and therefore could do so with the single purchase of an ETF. However, nearly all investors turn to ETFs as an investment vehicle to eliminate stock-specific risk and that is clearly not the case with BBH.

Of the five biotech ETFs, two that stand out above the others are XBI and PBE, because both have exposure to the large-cap names as well as some of the "junior" biotech stocks. By giving the ETF exposure to the small-cap and mid-cap names, it allows for the probability of owning a big winner, but at the same time one or two big losers will not ruin the returns of the ETF.

ETFs Win This Round
Right now, ETFs are clearly the better choice in the biotech sector for risk averse investors who would like to gain a true exposure to the entire arena. However, keep in mind you must look at the components of all ETFs before you consider making a purchase.

For related reading, see An Inside Look At ETF Construction.

Looking to cook up a market-stomping stock portfolio? Check out our FREE report "7 Ingredients to Market Beating Stocks" and get started right now!

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  4. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  5. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  6. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  7. Chart Advisor

    How Are You Trading The Breakdown In Growth Stocks? (VOOG, IWF)

    Based on the charts of these two ETFs, bearish traders will start turning their attention to growth stocks.
  8. Mutual Funds & ETFs

    Pimco’s Top Funds for Retirement Income

    Once you're living off the money you've saved for retirement, is it invested in the right assets? Here are some from PIMCO that may be good options.
  9. Chart Advisor

    Watch This ETF For Signs Of A Reversal (BCX)

    Trying to determine if the commodity markets are ready for a bounce? Take a look at the analysis of this ETF to find out if now is the time to buy.
  10. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  1. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  2. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  3. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
  4. Are Vanguard ETFs commission-free?

    While some Vanguard exchange-traded funds (ETFs) are available commission-free from third-party brokers, a large portion ... Read Full Answer >>
  5. Do Vanguard ETFs require a minimum investment?

    Vanguard completely waives any U.S. dollar minimum amounts to buy its exchange-traded funds (ETFs), and the minimum ETF investment ... Read Full Answer >>
  6. Can mutual fund expense ratios be negative?

    Mutual fund expense ratios cannot be negative. An expense ratio is the sum total of all fees charged by an asset management ... Read Full Answer >>
Trading Center